Aaron Lisberg

9.7k citations

71 papers · 1.8k indexed · 2 hit papers · h-index 18

Oncology top 2%
- Lung Cancer Research Studies 27
- Cancer Immunotherapy and Biomarkers 25
- HER2/EGFR in Cancer Research 11
Pulmonary and Respiratory Medicine top 2%
- Lung Cancer Treatments and Mutations 34
- Lung Cancer Diagnosis and Treatment 12
Radiology, Nuclear Medicine and Imaging top 5%
- Radiopharmaceutical Chemistry and Applications 6
Immunology top 10%
- Immunotherapy and Immune Responses 5
Cancer Research
Epidemiology
- Neuroendocrine Tumor Research Advances 5

Co-authors: Edward B. Garon Jonathan W. Goldman Krikor Bornazyan Narek Shaverdian Percy Lee Silvia C. Formenti Darlene Veruttipong Jacob Sands
Cited by: Oncology Pulmonary and Respiratory Medicine Radiology, Nuclear Medicine and Imaging
Journals: Journal of Clinical Oncology (19 papers)Journal of Thoracic Oncology (13 papers)Annals of Oncology (11 papers)
Partner nations: United States Japan France

In The Last Decade

Aaron Lisberg

62 papers receiving 1.7k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Aaron Lisberg

Since Specialization

Citations

This map shows the geographic impact of Aaron Lisberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aaron Lisberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aaron Lisberg more than expected).

Fields of papers citing papers by Aaron Lisberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aaron Lisberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aaron Lisberg. The network helps show where Aaron Lisberg may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Aaron Lisberg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Aaron Lisberg Line = papers co-authored together Aaron Lisberg links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Adequacy of Immune Checkpoint Inhibitor–Associated Thyroid Function Monitoring After Therapy JCO Oncology Practice ·Maria A. Velez,Nora Saidul Fatimah,多恵子丸岡,张辉利,حامد افشار,Nina Gong,Andy Han,X. F. Li,Daniel Li,Philippe Rochigneux,Tristan Grogan,David Elashoff,Edward B. Garon,Aaron Lisberg	2025	1
2	Brief Report: The Genomic Landscape of Small Cell Lung Cancer in Never-Smoking Patients Clinical Lung Cancer ·Michael S. Oh,Edward B. Garon,Aaron Lisberg,Amy L. Cummings,Alex Barrett,Gail Dechochai,M. Al-Kaff,Marcelo Chanes,Jonathan W. Goldman	2025	0
3	Characteristics of a CCL21 Gene–Modified Dendritic Cell Vaccine Utilized for a Clinical Trial in Non–Small Cell Lung Cancer Molecular Cancer Therapeutics ·Michael S. Oh,Camelia Dumitras,Ramin Salehi‐Rad,Linh M. Tran,Kostyantyn Krysan,Raymond J. Lim,许宜栋,Tatyana Vakhnenko,Aaron Lisberg,Edward B. Garon,Steven M. Dubinett,Bin Liu	2024	6
4	TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer Future Oncology ·Isamu Okamoto,Shoichi Kuyama,Nicolas Girard,Shun Lü,Fábio Franke,五十三山口,Pongwut Danchaivijitr,Ji‐Youn Han,Jong‐Mu Sun,Shunichi Sugawara,Edward Pan,Rümeysa Kabadayı,Saeko Machi,Jessica M Delamater,Aaron Lisberg	2024	6
5	LBA7 Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05 Annals of Oncology ·蔡纘榮,Jacob Sands,Aaron Lisberg,Luis Paz‐Ares,Breanne Bears,XU Honggu,Pheerawit Komchareon,Min Hee Hong,Shunichi Sugawara,Andreas Stavrou,Audrey Goutard,George R. Blumenschein,Elaine Shum,Qin Yiyan,Hong Zebger‐Gong,K. Lakshmi Narayanan,Sotiroula Chatzimatthaiou,Isamu Okamoto,Weili Gu	2024	6
6	Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan Cancer Treatment Reviews ·Rebecca S. Heist,Jacob Sands,Aditya Bardia,Toshio Shimizu,Aaron Lisberg,Ian E. Krop,Noboru Yamamoto,Takahiro Kogawa,Т.А. Кулагина,S. Fung,Anat Galor,فرح السطنبولي,Hocquett,英子岩本,Funda Meric‐Bernstam	2024	25
7	Analysis of drug-related interstitial lung disease (ILD) inpatients (pts) treated with datopotamab deruxtecan (Dato-DXd). Journal of Clinical Oncology ·Jacob Sands,Aaron Lisberg,Aditya Bardia,Toshio Shimizu,Myung‐Ju Ahn,Luis Paz‐Ares,総合教育系教授・歴史神学,Satoru Kitazono,Ian E. Krop,Nicolas Girard,Elvire Pons‐Tostivint,Rebecca S. Heist,Robin Cornelissen,Barbara Pistilli,Katie Lee,Paul Howarth,Liming Liu,Rick M. Fairhurst,Christina Khwela,Isamu Okamoto	2024	4
8	Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records Journal for ImmunoTherapy of Cancer ·F. K. R. LI-IN-ON,Vincent Amodru,Larasati Nur Kharomah,Jean‐Marie Boher,Christophe Zemmour,Brice Chanez,Anne-Sophie Chrétien,Laurent Gorvel,Gwénaëlle Gravis,M. EI-Monufy,Moises Ahmed Hassan,Anne Madroszyk,Thomas Cuny,Anthony Gonçalvès,Aaron Lisberg,Daniel Olive,V. Thamil Selvi,Frédéric Castinetti,Philippe Rochigneux	2023	4
9	518MO TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs) Annals of Oncology ·Satoru Kitazono,Luis Paz‐Ares,M-J. Ahn,Aaron Lisberg,Byoung Chul Cho,George R. Blumenschein,Elaine Shum,Breanne Bears,Yasushi Goto,Kiyotaka Yoh,Rebecca S. Heist,Paul Baas,David Planchard,M. Pérol,Enriqueta Felip,Wu‐Chou Su,Hong Zebger‐Gong,Lei Lan,O Yu Evdokimova,Jacob Sands	2023	8
10	Consent document translation expense hinders inclusive clinical trial enrolment Nature ·Maria A. Velez,Beth A. Glenn,Ana Rita Guedes Alves,Amy L. Cummings,Aaron Lisberg,Abdoulaye SOUMANA HIMA,Andika Putra Agustian,张辉利,Andreas Ho ̈lzer,蛭田三郎,Ezgi Durgun,X. F. Li,Mạnh Cầm Đỗ,Karen Kreutel,Jenny Brook,Tristan Grogan,David Elashoff,Michael A. Teitell,Edward B. Garon	2023	11
11	LBA12 Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01 Annals of Oncology ·M-J. Ahn,Aaron Lisberg,Luis Paz‐Ares,Robin Cornelissen,Nicolas Girard,Elvire Pons‐Tostivint,David Vicente Baz,Shunichi Sugawara,Manuel Cobo,M. Pérol,Céline Mascaux,Elena Poddubskaya,Satoru Kitazono,Hidetoshi Hayashi,Jacob Sands,Richard D. Hall,Yong Zhang,Hong Zebger‐Gong,Sotiroula Chatzimatthaiou,Isamu Okamoto	2023	34
12	First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01 Journal of Clinical Oncology ·Toshio Shimizu,Jacob Sands,Kiyotaka Yoh,Alexander I. Spira,Edward B. Garon,Satoru Kitazono,Melissa L. Johnson,Funda Meric‐Bernstam,Anthony W. Tolcher,Noboru Yamamoto,Jon Greenberg,Yui Kawasaki,Hong Zebger‐Gong,Fumiaki Kobayashi,Penny Phillips,Aaron Lisberg,Rebecca S. Heist	2023	76
13	Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer International Journal of Radiation OncologyBiologyPhysics ·Trudy C. Wu,Richard Eugene Templeton,Carol Felix,Denise K. Oseguera,Tahmineh Romero,Jonathan W. Goldman,Edward B. Garon,Jay M. Lee,John A. Glaspy,Aaron Lisberg,Chad G. Rusthoven,D. Ross Camidge,Shankar Siva,Benjamin Solomon,Alan Lee,Stephen Tenn,Narek Shaverdian,Michael L. Steinberg,Ann C. Raldow,Percy Lee	2023	15
14	509MO Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01 Annals of Oncology ·蔡纘榮,Aaron Lisberg,Luis Paz‐Ares,Robin Cornelissen,Nicolas Girard,Elvire Pons‐Tostivint,David Vicente Baz,Shunichi Sugawara,Manuel Cobo,M. Pérol,Céline Mascaux,Elena Poddubskaya,Satoru Kitazono,Hidetoshi Hayashi,Jacob Sands,Richard D. Hall,Yong Zhang,Hong Zebger‐Gong,Sotiroula Chatzimatthaiou,Isamu Okamoto	2023	11
15	Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer Clinical Cancer Research ·Philippe Rochigneux,Aaron Lisberg,Alejandro J. Garcia,Samuel Granjeaud,Anne Madroszyk,F. A. Sanchez,Anthony Gonçalvès,Raynier Devillier,Pauline Maby,D. S Rabinovich,Laurent Gorvel,Brice Chanez,Jaklin Gukasyan,James Carroll,Jonathan W. Goldman,Anne-Sophie Chrétien,Daniel Olive,Edward B. Garon	2022	20
16	Society of Interventional Radiology Multidisciplinary Position Statement on Percutaneous Ablation of Non-small Cell Lung Cancer and Metastatic Disease to the Lungs Journal of Vascular and Interventional Radiology ·Scott Genshaft,Robert D. Suh,Fereidoun Abtin,Mark O. Baerlocher,Albert J. Chang,Sean R. Dariushnia,A. Michael Devane,Salomão Faintuch,仁柳山,Aaron Lisberg,Siddharth A. Padia,Sheena Patel,Alda L. Tam,Jane Yanagawa	2021	30
17	Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer Clinical Cancer Research ·Siwen Hu‐Lieskovan,Aaron Lisberg,Jesse M. Zaretsky,Tristan Grogan,Hira Rizvi,Daniel K. Wells,James Carroll,Amy L. Cummings,John Madrigal,Benjamin Jones,Jaklin Gukasyan,I. Peter Shintaku,Dennis J. Slamon,Steven M. Dubinett,Jonathan W. Goldman,David Elashoff,Matthew D. Hellmann,Antoni Ribas,Edward B. Garon	2019	56
18	P1.04-33 Deep Phenotyping of Immune Populations Reveals Baseline Predictors of Pembrolizumab Efficacy in NSCLC on KEYNOTE-001 Journal of Thoracic Oncology ·Philippe Rochigneux,Aaron Lisberg,誠福田,Anne-Sophie Chrétien,F. A. Sanchez,Anne Madroszyk,Alice Tseng,袁廷贵,Jaklin Gukasyan,John Madrigal,Jonathan Carroll,Zorawar S. Noor,Amy L. Cummings,Daniel Olive,Edward B. Garon	2019	2
19	EP1.04-20 Phase I Trial of in Situ Vaccination with Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined with Pembrolizumab for Advanced NSCLC Journal of Thoracic Oncology ·Aaron Lisberg,J. Roemermann,Ramin Salehi‐Rad,ゆきこ渡邉,Linh M. Tran,Kostyantyn Krysan,R. Li,Ying Lin,申俊龙,Fereidoun Abtin,Robert D. Suh,Scott Oh,Denise R. Aberle,杨春皓,William D. Wallace,David Elashoff,Edward B. Garon,Sherven Sharma,Steven M. Dubinett	2019	2
20	P2.09-05 Evaluation of PD-L1-Stained Tumor Cells via the 22C3 and SP-142 Antibodies in Cohort of Patients Treated on KEYNOTE-001 Journal of Thoracic Oncology ·Aaron Lisberg,Siwen Hu‐Lieskovan,Tristan Grogan,James Carroll,Peter Shintaku,Maria Han,Dennis J. Slamon,S. Dubinett,Jonathan W. Goldman,David Elashoff,Matthew D. Hellmann,Antoni Ribas,Edward B. Garon	2018	2

About Aaron Lisberg

Aaron Lisberg is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 71 papers that have together received 1.8k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Research Studies (27 papers), Cancer Immunotherapy and Biomarkers (25 papers), Lung Cancer Diagnosis and Treatment (12 papers), HER2/EGFR in Cancer Research (11 papers), Radiopharmaceutical Chemistry and Applications (6 papers), Immunotherapy and Immune Responses (5 papers) and Neuroendocrine Tumor Research Advances (5 papers). The work is most often cited by research in Oncology (1.4k citations), Pulmonary and Respiratory Medicine (879 citations) and Radiology, Nuclear Medicine and Imaging (296 citations). Aaron Lisberg has collaborated with scholars based in United States, Japan and France. Frequent co-authors include Edward B. Garon, Jonathan W. Goldman, Krikor Bornazyan, Narek Shaverdian, Percy Lee, Silvia C. Formenti, Darlene Veruttipong, Jacob Sands, Funda Meric‐Bernstam and Toshio Shimizu. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, Cancer Research and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact